Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 20/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.66 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.64 |
| ▸ | OXTR | P30559 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25303909 | 1.00 | AVPR1A (0.68) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL25299972 | 0.90 | AVPR1A (0.66) | AVPR1AKCNH2AVPR2 | |
| SCHEMBL25299973 | 0.90 | AVPR1A (0.66) | AVPR1AKCNH2AVPR2 | |
| SCHEMBL25252070 | 0.90 | AVPR1A (0.64) | AVPR1AKCNH2AVPR2 | |
| SCHEMBL25258820 | 0.90 | AVPR1A (0.64) | AVPR1AKCNH2AVPR2 | |
| SCHEMBL25301736 | 0.89 | AVPR1A (0.64) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL25418930 | 0.89 | AVPR1A (0.64) | AVPR1AKCNH2AVPR2OXTR | |
| SCHEMBL25835733 | 0.88 | AVPR1A (0.55) | AVPR1AKCNH2AVPR2 | |
| SCHEMBL25294523 | 0.87 | AVPR1A (0.62) | AVPR1AKCNH2AVPR2 | |
| SCHEMBL30356766 | 0.87 | AVPR1A (0.62) | AVPR1AKCNH2AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185570-B1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2024-10-09 | — | — | EP | claimed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | claimed |
| EP-4185570-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | claimed |
| EP-4185570-B1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2024-10-09 | — | — | EP | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4185570-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885KCNH2 2524/4885AVPR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.